Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer Patients
Sponsor: National University Hospital, Singapore
A PHASE2/PHASE3 clinical study on Asian Colorectal Cancer Patients, this trial is ongoing. The trial is conducted by National University Hospital, Singapore and has accumulated 5 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Jan 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National University Hospital, Singapore
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Singapore, Singapore